Neil's Feed
Aug 26, 2015
via Breakingviews

Monsanto leaves Syngenta facing awkward questions

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Monsanto’s abandonment of Syngenta may turn out to be the best thing for both sides. The world’s largest seed maker has given up its $46 billion pursuit of the Swiss agricultural chemical group. Syngenta’s management must now show why its reluctance to entertain the offer was well founded.

Aug 26, 2015
via Breakingviews

Monsanto leaves Syngenta facing awkward questions

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Monsanto’s abandonment of Syngenta may turn out to be the best thing for both sides. The world’s largest seed maker has given up its $46 billion pursuit of the Swiss agricultural chemical group. Syngenta’s management must now show why its reluctance to entertain the offer was well founded.

Aug 21, 2015
via Breakingviews

Glaxo sale comes with cheeky earnings side effect

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

GlaxoSmithKline’s smart sale of a developmental drug comes with a cheeky earnings side effect. The UK pharmaceutical firm is selling a multiple sclerosis treatment to Novartis for up to $1 billion. It’s a logical move, but revives debate over how pharma groups account for one-off deals.

Aug 11, 2015
via Breakingviews

Greece deal leaves euro intact but fragile

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Is the euro zone unbreakable? With Greece close to getting a new bailout, it at least looks more robust than it did. The risk is less about the exit of a peripheral state, and more about the economic rifts between core members.

Aug 11, 2015
via Breakingviews

Greece deal leaves euro intact but fragile

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Is the euro zone unbreakable? With Greece close to getting a new bailout, it at least looks more robust than it did. The risk is less about the exit of a peripheral state, and more about the economic rifts between core members.

Aug 4, 2015
via Breakingviews

Shire M&A machine stumbles on $30 bln Baxalta bid

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Shire’s M&A machine has taken a gentle knock. The onetime Irish target for AbbVie is planning a mega-deal of its own. Yet unlike the previous combination, Shire’s $30 billion lunge for Baxalta carries a fair slug of industrial logic, as well as tax benefits. Its shareholders, though, still need some persuading.

Aug 4, 2015
via Breakingviews

Shire M&A machine stumbles on $30 bln Baxalta bid

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Shire’s M&A machine has taken a gentle knock. The onetime Irish target for AbbVie is planning a mega-deal of its own. Yet unlike the previous combination, Shire’s $30 billion lunge for Baxalta carries a fair slug of industrial logic, as well as tax benefits. Its shareholders, though, still need some persuading.

Jul 29, 2015
via Breakingviews

Novartis spinoff is neat cure for Big Pharma ills

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Biotech investors can be better at valuing and nurturing small drugs than Big Pharma. Recognising this, Novartis is spinning three drugs-in-development into a new entity backed by UK investors. With biotech markets hot, there’s room for copycat deals.

Jul 29, 2015
via Breakingviews

Novartis spinoff is neat cure for Big Pharma ills

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Biotech investors can be better at valuing and nurturing small drugs than Big Pharma. Recognising this, Novartis is spinning three drugs-in-development into a new entity backed by UK investors. With biotech markets hot, there’s room for copycat deals.

Jul 27, 2015
via Breakingviews

Teva exits Mylan mess with $40.5 bln Allergan deal

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Teva has found a neat exit from its Mylan mess. The Israeli pharmaceutical firm has been locked in a bitter battle to take over the Dutch drugmaker. Now it has agreed to buy the generic business from Allergan for $40.5 billion. The swap makes sense.